An observational study in Pregnancy Related and Atopic Dermatitis, sponsored by Incyte Corporation. Recruiting at 1 site in United States. Open to female participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by Incyte Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Dermatitis, Atopic by Incyte Corporation — 2 open to participants now, 3 under way, 1 of them phase 3. Dermatitis, Atopic · Incyte Corporation.
Among the 17 studies in Dermatitis, Atopic by Incyte Corporation, this one is one of 4 that started in 2023, is one of 3 observational ones, and was the 14th registered.
1,592 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 17 studies in Dermatitis, Atopic by Incyte Corporation are open now, in 1 country. Recruiting first, the newest first:
Incyte Corporation · Sites in United States
Ages 14+ · Women only
By country, each count listing its studies:
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 15 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 958 is above the median of 150 across 283 observational studies indexed under Dermatitis, Atopic.
Median enrollment 90 across the 14 interventional studies, 958 across the 3 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
1 of the studies in Dermatitis, Atopic by Incyte Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06627335Incyte CorporationAn Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis | 2027-08-15 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Dermatitis, Atopic by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.
This study is an exposure cohort study of women within the US with AD who were exposed to ruxolitinib cream at any time during their pregnancy period, defined as up to 24 days prior to the estimated date of conception (DOC) through the end of pregnancy, compared with women in the US with Atopic Dermatitis (AD) not exposed to ruxolitinib cream during pregnancy. The DOC is estimated to occur 14 days after the last menstrual period (LMP). Eligible pregnant women may self-enroll or voluntarily be enrolled by their health care provider (HCP) by calling Syneos Health. Enrollment should occur as early in pregnancy as possible.
Exposure cohort study of women within the US with atopic dermatitis (AD) who were exposed to ruxolitinib cream at any time during their pregnancy period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Information available to confirm eligibility for either the exposed to ruxolitinib cream cohort or the not exposed to ruxolitinib cream cohort.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ruxolitinib Cream
Drug: Ruxolitinib Cream
Ruxolitinib Cream
Also known as: Opzelura
Number of major congenital malformation (MCM)s
Defined as any major structural or chromosomal defect in live-born infants, stillbirths or spontaneous losses equal to or greater than 20 weeks' gestation, or electively terminated pregnancies of any gestational age.
Time frame: Up to 12 months after birth
Number of minor congenital malformations
Defined as abnormalities that do not significantly affect health and development, and normal variants are ascertained only among those who also have a major defect.
Time frame: Up to 12 months after birth
Number of Pregnancy outcomes
Number of live births, still births, recognized spontaneous abortions and number of elective terminations as defined in the protocol.
Time frame: Up to birth
Adverse pregnancy outcomes
Number of preterm births and maternal pregnancy complications as defined in the protocol.
Time frame: Up to birth
Gestational Age
Infant Gestational Age at birth as recorded in medical records.
Time frame: At time of delivery
Infant Sex
Infant Sex at birth as recorded in the medical records.
Time frame: At time of delivery
Infant Body Weight
Infant Body Weight at birth as recorded in medical records.
Time frame: At time of delivery
Infant Body Length
Infant Body Length at birth as recorded in medical records.
Time frame: At time of delivery
Infant Head Circumference
Infant Head Circumference at birth as recorded in medical records.
Time frame: At time of delivery
APGAR Score
One and five minute APGAR Scores at birth as recorded in medical records.
Time frame: At time of delivery
Number of small for gestational age (SGA)s
Defined as a birthweight at or below the 10th percentile for a given gestational age.
Time frame: At time of delivery
Infant Body Length
Infant Body Length as recorded in medical records.
Time frame: Through 12 months after birth
Infant Body Weight
Infant Body Weight as recorded in medical records.
Time frame: Through 12 months after birth
Infant Head Circumference
Infant Head Circumference as recorded in medical records.
Time frame: Through 12 months after birth
Abnormal development
Based on Centers for Disease Control and Prevention (CDC) developmental milestones.
Time frame: Through 12 months after birth
Plan to share: No
Started Sep 2023 (actual). Primary completion is estimated for Aug 2032, 106 months after the start.
Of 74 industry-sponsored observational studies under Dermatitis, Atopic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 84. This study's planned 106 months is above that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.